• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Corvus Pharmaceuticals Inc.

    5/7/26 5:02:36 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVS alert in real time by email
    S-8 1 tm2613947d1_s8.htm FORM S-8

    As filed with the Securities and Exchange Commission on May 7, 2026

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Corvus Pharmaceuticals, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of

    incorporation or organization)

     

    46-4670809

    (I.R.S. Employer

    Identification Number)

     

    901 Gateway Boulevard, Third Floor

    South San Francisco, CA 94080

    (650) 900-4520

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

     

     

    2016 Equity Incentive Award Plan

    (Full Title of the Plan)

     

     

     

    Richard A. Miller, M.D.

    President and Chief Executive Officer

    Corvus Pharmaceuticals, Inc.

    901 Gateway Boulevard, Third Floor

    South San Francisco, CA 94080

    (650) 900-4520

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Kathleen Wells, Esq.
    Latham & Watkins LLP
    801 Jefferson Ave., Suite 300
    Redwood City, CA 94063

    Telephone: (650) 328-4600
    Facsimile: (650) 463-2600

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

    Proposed sale to take place as soon after the effective date of the

    registration statement as awards under the plans are exercised and/or vest.

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,987,865 shares of the Registrant’s common stock issuable under the 2016 Equity Incentive Plan, for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933, 333-255614, 333-264718, 333-270910, 333-279189 and 333-287109) are effective, as a result of the operation of an automatic annual increase provision therein.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON

    FORM S-8

     

    Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 29, 2016, March 10, 2017, March 13, 2018, May 9, 2019, April 30, 2020, April 29, 2021, May 5, 2022, March 28, 2023, May 7, 2024, and May 8, 2025  (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933, 333-255614, 333-264718, 333-270910, 333-279189 and 333-287109) are incorporated by reference herein.

     

     

     

     

    Exhibit Index

           

    Incorporated by Reference

     
       
           

    Filed Herewith

     

    Exhibit
    Number

      Exhibit Description   Form    Date   Number    
    4.1   Amended and Restated Certificate of Incorporation.   8-K   3/29/2016   3.1    
    4.2   Amended and Restated Bylaws.   8-K   3/29/2016   3.2    
    4.3   Form of Common Stock Certificate.   S-1   1/4/2016   4.2    
    5.1   Opinion of Latham & Watkins LLP.               X
    23.1   Consent of independent registered public accounting firm.               X
    23.2   Consent of Latham & Watkins LLP (included in Exhibit 5.1).               X
    24.1   Power of Attorney. Reference is made to the signature page to the Registration Statement.               X
    99.1(a)#   2016 Equity Incentive Award Plan.   S-8   3/29/2016   99.2(a)    
    99.1(b)#   Form of Stock Option Grant Notice and Stock Option Agreement under the 2016 Equity Incentive Award Plan.   S-1   1/4/2016   10.5(b)    
    99.1(c)#   Form of Restricted Stock Award Agreement and Restricted Stock Unit Award Agreement under the 2016 Equity Incentive Award Plan.   S-1   1/4/2016   10.5(c)    
    99.1(d)#   Form of Restricted Stock Unit Award Agreement and Restricted Stock Unit Award Grant Notice under the 2016 Equity Incentive Award Plan.   S-1   1/4/2016   10.5(d)    
    107.1   Calculation of Filing Fee Table               X
                         
        #Indicates management contract or compensatory plan.                

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 7th day of May, 2026.  

     

      Corvus Pharmaceuticals, Inc.
       
      By:

    /s/ Richard A. Miller

        Richard A. Miller, M.D.
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Richard A. Miller, M.D. and Leiv Lea, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

             
    Signature   Title   Date
             

    /s/ Richard A. Miller

     

    Richard A. Miller M.D.

      President, Chief Executive Officer and Director
    (Principal Executive Officer)
      May 7, 2026
             

    /s/ Leiv Lea

     

    Leiv Lea

      Chief Financial Officer
    (Principal Financial and Accounting Officer)
      May 7, 2026
             

    /s/ Andrew C. Chan, M.D., Ph.D.

     

    Andrew C. Chan, M.D., Ph.D.

      Director   May 7, 2026
             

    /s/ Ian T . Clark

     

    Ian T . Clark

      Director   May 7, 2026
             

    /s/ Linda S. Grais, M.D., J.D.

     

    Linda S. Grais, M.D., J.D.

      Director   May 7, 2026
             

    /s/ David Moore

     

    David Moore

      Director   May 7, 2026
             

    /s/ Peter Thompson, M.D.

     

    Peter Thompson, M.D.

      Director   May 7, 2026
             

    /s/ Richard A. van den Broek

     

    Richard A. van den Broek

      Director   May 7, 2026

     

     

    Get the next $CRVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRVS

    DatePrice TargetRatingAnalyst
    4/17/2026$40.00Buy
    Goldman
    10/13/2025$16.00Overweight
    Barclays
    1/2/2025$11.00Buy
    H.C. Wainwright
    8/18/2023$7.00Outperform
    Oppenheimer
    12/3/2021$5.00 → $8.00Overweight
    Cantor Fitzgerald
    12/1/2021$8.00Buy
    Jefferies
    8/3/2021$4.00 → $3.50Neutral
    Mizuho
    7/16/2021$9.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Miller Richard A Md bought $83,453 worth of shares (6,932 units at $12.04) (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    5/20/26 4:12:25 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    5/7/24 5:06:34 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    5/7/24 5:05:52 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET. A webcast of the presentations will be available live and for 90 days fol

    5/20/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

    New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and clinical results SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceut

    5/14/26 7:00:00 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

    Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting the potential for drug-free remissions with soquelitinib to be presented at Society for Investigative Dermatology (SID) annual meeting Company hosting investor and analyst meeting to review SID data on May 14, 2026 at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2

    5/7/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Corvus Pharmaceuticals with a new price target

    Goldman initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    4/17/26 8:10:40 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Corvus Pharmaceuticals with a new price target

    Barclays initiated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $16.00

    10/13/25 8:52:40 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Corvus Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $11.00

    1/2/25 7:32:41 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.

    SCHEDULE 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    5/15/26 4:13:58 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

    5/14/26 7:01:18 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Corvus Pharmaceuticals Inc.

    S-8 - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

    5/7/26 5:02:36 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Miller Richard A Md bought $83,453 worth of shares (6,932 units at $12.04) (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    5/20/26 4:12:25 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chan Andrew C.

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    4/27/26 5:32:20 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chan Andrew C.

    3 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    4/27/26 5:31:41 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Financials

    Live finance-specific insights

    View All

    Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

    Two oral presentations including late-breaker at SID  Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor and analyst meeting scheduled for 1:30 pm ET (12:30 pm CT) on May 14, 2026 Company to report first quarter 2026 financial results on May 7, 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that it will host an in-person and virtual investor and analyst meeting on May 14, 2026 to highlight soquelitinib data being presented at the Society for Investiga

    4/21/26 7:30:00 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

    Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment  75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients who have received prior systemic therapy including patients who are treatment resistant Company to host conference call and webcast today at 8:00 am ET / 5:00 am PT SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced positive results from cohort 4 of the randomized,

    1/20/26 7:00:00 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc.

    SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    8/1/24 9:18:47 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    5/13/24 4:52:14 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corvus Pharmaceuticals Inc.

    SC 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    5/9/24 5:29:29 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Leadership Updates

    Live Leadership Updates

    View All

    Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

    SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology. "The addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for ITK inhibi

    4/23/26 7:30:00 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Corvus Pharmaceuticals Appoints David Moore to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company's Board of Directors. Mr. Moore brings a wealth of experience from his 27-year career in the industry, including broad expertise across strategy, commercial, market access, business development and investing from working in both large cap pharmaceutical and biotech companies and within private equity. "We are excited to welcome David to the Board," said Richard A. Miller, M.D., c

    10/2/25 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care